Search Result

Results for "

Auristatin E

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (3) ADC Cytotoxin (9) ADC Linker (4) Antibody-Drug Conjugates (ADCs) (10) Apoptosis (3) c-Met/HGFR (1) Drug Intermediate (8) Drug-Linker Conjugates for ADC (23) EGFR (3) Microtubule/Tubulin (33) Peptide-Drug Conjugates (PDCs) (1) PROTAC Linkers (1) TNF Receptor (1) TRP Channel (1)
By Research Areas:	Cancer (71) Inflammation/Immunology (1)
Click Chemistry:	ADC Synthesis (1) DBCO (3) Azide (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15582

Auristatin E	Microtubule/Tubulin ADC Cytotoxin	Cancer
Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .

HY-145989S

*Aminobenzenesulfonic auristatin* E-d8**	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
Aminobenzenesulfonic auristatin E-d₈ is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1][2].

HY-145989A

*Aminobenzenesulfonic auristatin* E TFA**	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
Aminobenzenesulfonic auristatin E TFA is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E TFA has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .

HY-49413

*Monomethyl auristatin* E intermediate-2**	Microtubule/Tubulin	Cancer
Monomethyl auristatin E intermediate-2 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-78908

*Monomethyl auristatin* E intermediate-11**	Microtubule/Tubulin	Cancer
Monomethyl auristatin E intermediate-11 is an intermediate reactant in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-33048

*Monomethyl auristatin* E intermediate-1**	Microtubule/Tubulin	Cancer
Monomethyl auristatin E intermediate-1 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-15582G

Auristatin E	Microtubule/Tubulin ADC Cytotoxin	Cancer
Auristatin E (GMP) is Auristatin E (HY-15582) produced by using GMP guidelines. Auristatin E is a tubulin polymerization inhibitor .

HY-145989

*Aminobenzenesulfonic auristatin* E**	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
Aminobenzenesulfonic auristatin E is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .

HY-78903A

*Monomethyl auristatin* E intermediate-10**	Microtubule/Tubulin	Cancer
Monomethyl auristatin E intermediate-10 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-79205

*Monomethyl auristatin* E intermediate-17**	Microtubule/Tubulin	Cancer
Monomethyl auristatin E intermediate-17 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-78903

*Monomethyl auristatin* E intermediate-9**	Microtubule/Tubulin Drug Intermediate	Cancer
Monomethyl auristatin E intermediate-9 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-78901A

*Monomethyl auristatin* E intermediate-8**	Microtubule/Tubulin	Cancer
Monomethyl auristatin E intermediate-8 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-78911

*Monomethyl auristatin* E intermediate-13**	Microtubule/Tubulin	Cancer
Monomethyl auristatin E intermediate-13 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-79196

*Monomethyl auristatin* E intermediate-15**	Microtubule/Tubulin	Cancer
Monomethyl auristatin E intermediate-15 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-79198

*Monomethyl auristatin* E intermediate-16**	Microtubule/Tubulin Drug Intermediate ADC Cytotoxin	Cancer
Monomethyl auristatin E intermediate-16 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-78910

*Monomethyl auristatin* E intermediate-12**	Microtubule/Tubulin	Cancer
Monomethyl auristatin E intermediate-12 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-43147

*Monomethyl auristatin* E intermediate-4**	Microtubule/Tubulin	Cancer
Monomethyl auristatin E intermediate-4 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-78899

*Monomethyl auristatin* E intermediate-6**	Microtubule/Tubulin Drug Intermediate	Cancer
Monomethyl auristatin E intermediate-6 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-78901

*Monomethyl auristatin* E intermediate-7**	Microtubule/Tubulin	Cancer
Monomethyl auristatin E intermediate-7 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-43149

*Monomethyl auristatin* E intermediate-5**	Microtubule/Tubulin	Cancer
Monomethyl auristatin E intermediate-5 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-78913

*Monomethyl auristatin* E intermediate-14**	ADC Cytotoxin	Cancer
Monomethyl auristatin E intermediate-14 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-43146

*Monomethyl auristatin* E intermediate-3**	Microtubule/Tubulin	Cancer
Monomethyl auristatin E intermediate-3 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-128899

*MC-Val-Cit-PAB-Auristatin* E**	Drug-Linker Conjugates for ADC	Cancer
MC-Val-Cit-PAB-Auristatin E is a agent-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker MC-Val-Cit-PAB.

HY-15162G

Monomethyl auristatin E MMAE; SGD-1010; Vedotin	Microtubule/Tubulin Apoptosis ADC Cytotoxin	Cancer
Monomethyl auristatin E (MMAE) (GMP) is Monomethyl auristatin E (HY-15162) produced by using GMP guidelines. Monomethyl auristatin E is a tubulin polymerization inhibitor .

HY-78899A

*(4R,5S)-Monomethyl auristatin* E intermediate-6**	Microtubule/Tubulin	Cancer
(4R,5S)-Monomethyl auristatin E intermediate-6 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .

HY-15162R

*Monomethyl auristatin* E (Standard)** MMAE (Standard); SGD-1010 (Standard); Vedotin (Standard)	Microtubule/Tubulin Apoptosis	Cancer
Monomethyl auristatin E (MMAE) (Standard) is the analytical standard of Monomethyl auristatin E (HY-15162). This product is intended for research and analytical applications. Monomethyl auristatin E is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) against several different cancer types .

HY-15162

*Monomethyl auristatin* E** 40+ Cited Publications MMAE; SGD-1010; Vedotin	Microtubule/Tubulin ADC Cytotoxin Apoptosis	Cancer
Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.

HY-100566

SuO-Val-Cit-PAB-MMAE 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
SuO-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB .

HY-156712

Depatuxizumab MMAE	Antibody-Drug Conjugates (ADCs)	Cancer
Depatuxizumab MMAE is an antibody-drug conjugate (ADC) comprising an anti EGFR monoclonal antibody (Depatuxizumab) and the cytotoxic agent Monomethyl auristatin E (MMAE). Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR .

HY-172820

Trastuzumab envedotin DP303c	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab envedotin (DP303c) is a anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab envedotin is composed of the tubulin polymerization inhibitor Monomethyl auristatin E (MMAE) (HY-15162) to the anti-HER2 antibody DP001 via a cleavable linker. Trastuzumab envedotin can be used for the research of HER2-positive solid tumors, such as breast cancer, colorectal cancer, and gastric cancer .

HY-152963

Tisotumab vedotin	Antibody-Drug Conjugates (ADCs)	Inflammation/Immunology Cancer
Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer .

HY-78931

Boc-Dap-NE	ADC Linker	Cancer
Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-78931G

Boc-Dap-NE	ADC Linker	Cancer
Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-78932

Dap-NE	ADC Cytotoxin	Cancer
Dap-NE is an intermediate reagent in the synthesis of the ADC toxin Monomethyl auristatin E (HY-15162) .

HY-78931F

(R,S,S,S,R)-Boc-Dap-NE	Drug Intermediate	Cancer
(R,S,S,S,R)-Boc-Dap-NE is an isomer of the dipeptide Boc-Dap-NE (HY-78931). Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-78931C

(S,S,R,S,R)-Boc-Dap-NE	Drug Intermediate	Cancer
(S,S,R,S,R)-Boc-Dap-NE is an isomer of the dipeptide Boc-Dap-NE (HY-78931). Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-78931E

(R,S,R,S,R)-Boc-Dap-NE	Drug Intermediate	Cancer
(R,S,R,S,R)-Boc-Dap-NE is an isomer of the dipeptide Boc-Dap-NE (HY-78931). Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-78931B

(S,S,S,S,R)-Boc-Dap-NE	Drug Intermediate	Cancer
(S,S,S,S,R)-Boc-Dap-NE is the inactive isomer of Boc-Dap-NE (HY-78931), and can be used as an experimental control. Boc-Dap-NE, is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-78931A

(R,S,S,R,S)-Boc-Dap-NE	Drug Intermediate	Cancer
(R,S,S,R,S)-Boc-Dap-NE is the inactive isomer of Boc-Dap-NE (HY-78931), and can be used as an experimental control. Boc-Dap-NE, is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-141860

PSMA-Val-Cit-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
PSMA-Val-Cit-PAB-MMAE is a novel small-molecule PSMA-targeted conjugate based on the monomethyl auristatin E for the chemotherapy of prostate cancer.

HY-15741

Mc-MMAE Maleimidocaproyl-monomethylAuristatin E	Microtubule/Tubulin Drug-Linker Conjugates for ADC	Cancer
Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a agent-linker conjugate for ADC.

HY-78933

Fmoc-MMAE	Microtubule/Tubulin ADC Cytotoxin	Cancer
Fmoc-MMAE is a protective group-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Fmoc-MMAE can be used in the synthesis of ADC .

HY-153428

GGGDTDTC-Mc-vc-PAB-MMAE	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
GGGDTDTC-Mc-vc-PAB-MMAE is a Drug-Linker Conjugate for ADC, containing a tubulin inhibitor Monomethyl auristatin E (MMAE, HY-15162) .

HY-157284

Cys-mc-MMAE	Drug-Linker Conjugates for ADC	Cancer
Cys-mc-MMAE is a Drug-Linker Conjugates for ADC, and consists of Monomethyl auristatin E (HY-15162) and a linker. Cys-mc-MMAE can be used for synthesis of ADCs .

HY-160702

DMBA-SIL-Mal-MMAE	Drug-Linker Conjugates for ADC	Cancer
DMBA-SIL-Mal-MMAE is a cytotoxin-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked DMBA-SIL-Mal .

HY-126681

SC-VC-PAB-MMAE 2 Publications Verification NHS-VC-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
SC-VC-PAB-MMAE is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB .

HY-153976

Fmoc-Gly3-VC-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
Fmoc-Gly3-VC-PAB-MMAE is a Drug-Linker Conjugates for ADC. Fmoc-Gly3-VC-PAB-MMAE consists of Monomethyl auristatin E (HY-15162) and a linker .

HY-171060

Mc-Pro-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
Mc-Pro-PAB-MMAE is a Drug-Linker Conjugate for ADC. Mc-Pro-PAB-MMAE consists of Monomethyl auristatin E (HY-15162) and a linker. Mc-Pro-PAB-MMAE can be used for synthesis of ADCs .

HY-15575

VcMMAE Maximum Cited Publications 58 Publications Verification MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).

HY-126686

Mal-Phe-C4-VC-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
Mal-Phe-C4-VC-PAB-MMAE is made by MMAE conjugated to Mal-Phe-C4-VC-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate.

Cat. No.	Product Name	Type

HY-15162G

*Monomethyl auristatin* E (GMP)** MMAE (GMP); SGD-1010 (GMP); Vedotin (GMP)	Fluorescent Dye
Monomethyl auristatin E (MMAE) (GMP) is Monomethyl auristatin E (HY-15162) produced by using GMP guidelines. Monomethyl auristatin E is a tubulin polymerization inhibitor .

HY-15582G

Auristatin E (GMP)	Fluorescent Dye
Auristatin E (GMP) is Auristatin E (HY-15582) produced by using GMP guidelines. Auristatin E is a tubulin polymerization inhibitor .

HY-78931G

Boc-Dap-NE (GMP)	Fluorescent Dye
Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-78738G

MC-Val-Cit-PAB (GMP)	Fluorescent Dye
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.

Cat. No.	Product Name	Type

HY-15162G

*Monomethyl auristatin* E (GMP)** MMAE (GMP); SGD-1010 (GMP); Vedotin (GMP)	Biochemical Assay Reagents
Monomethyl auristatin E (MMAE) (GMP) is Monomethyl auristatin E (HY-15162) produced by using GMP guidelines. Monomethyl auristatin E is a tubulin polymerization inhibitor .

HY-15582G

Auristatin E (GMP)	Biochemical Assay Reagents
Auristatin E (GMP) is Auristatin E (HY-15582) produced by using GMP guidelines. Auristatin E is a tubulin polymerization inhibitor .

HY-78931G

Boc-Dap-NE (GMP)	Biochemical Assay Reagents
Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-78738G

MC-Val-Cit-PAB (GMP)	Biochemical Assay Reagents
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.

Cat. No.	Product Name	Target	Research Area

HY-P10740

CBP-1018	Peptide-Drug Conjugates (PDCs) TRP Channel	Cancer
CBP-1018 is a PDC (peptide drug conjugate) consisting of a dual targeting FRα/TRPV6 ligand (blue part) coupled to Monomethyl auristatin E (HY-15162) (red part) via a linker (HY-78738) (black part). CBP-1018 is expected to be used in breast cancer research .

Cat. No.	Product Name	Target	Research Area

HY-P99970

Lifastuzumab	ADC Antibody	Others
Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity .

HY-P99205

Glembatumumab	ADC Antibody	Cancer
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .

HY-132253

Polatuzumab vedotin	Antibody-Drug Conjugates (ADCs)	Cancer
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .

HY-P99151

Brentuximab	ADC Antibody TNF Receptor	Cancer
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC₅₀ of 10 nM against human CD30+ cancer cells .

HY-P99595

Sirtratumab vedotin AGS15E; ASG-15ME; 1vcMMAE	Antibody-Drug Conjugates (ADCs)	Cancer
Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker .

HY-P99705

Lifastuzumab vedotin RG-7599; DNIB-0600A; NaPi2b-ADC	Antibody-Drug Conjugates (ADCs)	Cancer
Lifastuzumab vedotin (RG-7599; DNIB0600A) is an antibody-drug conjugate (ADC) that comprises a humanized IgG1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. Lifastuzumab vedotin has the potential for non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) research .

Cat. No.	Product Name	Chemical Structure

HY-145989S

*Aminobenzenesulfonic auristatin* E-d8**
Aminobenzenesulfonic auristatin E-d₈ is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1][2].

HY-15162A

MMAE-d8 5+ Cited Publications
MMAE-d₈ is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.

HY-15575S

VcMMAE-d8
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81056

	MMAE Antibody (YA899) MMAE; Monomethyl Auristatin E; MonomethylAuristatin E; MonomethylAuristatin norephedrine; Toxin MMAE; MMAE toxin	ELISA	Species independent
	MMAE Antibody (YA899) is an unconjugated, rabbit-derived, anti-MMAE (YA899) monoclonal antibody. MMAE Antibody (YA899) can be used for: ELISA expriments without labeling.

Compare Products

Products

Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample
Size

Cat. No.	Product Name		Classification

HY-126690

DBCO-(PEG2-VC-PAB-MMAE)2		DBCO
DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate . DBCO-(PEG2-VC-PAB-MMAE)2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-111012

DBCO-(PEG)3-VC-PAB-MMAE 2 Publications Verification		ADC Synthesis DBCO
DBCO-(PEG)3-VC-PAB-MMAE is a agent-linker conjugate for ADC. DBCO-(PEG)3-VC-PAB-MMAE is made by Monomethyl auristatin E (HY-15162) conjugats to DBCO-(PEG)3-vc-PAB linker. DBCO-(PEG)3-VC-PAB-MMAE can be used for the research of cancer . DBCO-(PEG)3-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-W190943

Azido-PEG4-Val-Cit-PAB-MMAE		Azide
Azido-PEG4-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH . Azido-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-164309

DBCO-PEG3-Glu-Val-Cit-PABC-MMAE		DBCO
DBCO-PEG3-Glu-Val-Cit-PABC-MMAE is a drug-linker conjugate for ADC. DBCO-PEG3-Glu-Val-Cit-PABC-MMAE contains a potent tubulin inhibitor Monomethyl auristatin E (MMAE, HY-15162) and can be used for synthesis of dual-drug ADC .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks